Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.
By L. Nieman, B. Biller, J. Findling, M. H. Murad, J. Newell-Price, Martin O. Savage, A. Tabarin. Journal of Clinical Endocrinology and Metabolism, 2015
1,076 citations recorded by the source corpus.
OBJECTIVE The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. PARTICIPANTS Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. EVIDENCE The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/4d26bfff9a2f2ea132ea661d03d84dc8b2293884
Citations in the corpus
- Consensus on Diagnosis and Management of Cushing’s Disease: A Guideline Update (2021, neutral): “Radiotherapy is primarily used as adjuvant therapy for patients with persistent or recurrent disease after trans sphenoidal surgery 7,245 or for aggressive tumour growth.”